Agistatin B is primarily researched for its potential in cancer therapy due to its ability to inhibit angiogenesis, the process by which new blood vessels form from pre-existing vessels. This property is crucial in halting the growth and spread of tumors, as it effectively starves them of necessary nutrients and oxygen. Additionally, Agistatin B has shown promise in reducing inflammation, making it a candidate for treating inflammatory diseases. Its application in these areas is still under investigation, with ongoing studies aimed at understanding its full therapeutic potential and optimizing its efficacy in clinical settings.